Opexa Therapeutics, Inc. Announces Closing of Partial Exercise of
Underwriters’ Option to Purchase Additional Shares of Common Stock
THE WOODLANDS, Texas -- September 4, 2013
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing
Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple
sclerosis (MS), today announced the closing of the partial exercise of the
over-allotment option granted to the underwriters to purchase an additional
650,000 shares of its common stock, at a price to the public of $1.50 per
share, in connection with the Company’s recently announced underwritten public
offering of 12,000,000 shares of common stock, bringing total gross proceeds
from the offering to $18,975,000, before deducting underwriting discounts and
commissions and other offering expenses payable by the Company.
Aegis Capital Corp. acted as sole book-running manager for the offering.
A registration statement relating to these securities was declared effective
by the Securities and Exchange Commission on August 7, 2013. The offering was
made only by means of a prospectus. Copies of the prospectus relating to the
offering are available on the SEC’s website at http://www.sec.gov. Copies of
the prospectus may also be obtained from the offices of Aegis Capital Corp.,
Prospectus Department, 810 Seventh Avenue, 18^th Floor, New York, NY, 10019,
via telephone at (212) 813-1010, or via email at email@example.com.
This press release does not constitute an offer to sell or the solicitation of
an offer to buy these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale is not permitted.
Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning
the interests of patients, employees and shareholders. The Company’s leading
therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in
a Phase IIb clinical development program (the Abili-T trial) for the treatment
of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the
patient’s peripheral blood, expanded ex vivo, and reintroduced into the
patients via subcutaneous injections. This process triggers a potent immune
response against specific subsets of autoreactive T-cells known to attack
About Multiple Sclerosis (MS)
Multiple Sclerosis is a chronic, inflammatory condition of the central nervous
system and is the most common, non-traumatic, disabling neurological disease
in young adults. It is estimated that approximately two million people have MS
While symptoms can vary, the most common symptoms of MS include blurred
vision, numbness or tingling in the limbs and problems with strength and
coordination. The relapsing forms of MS are the most common. The Secondary
Progressive form of MS represents about a third of the MS patient population.
Tcelna® is a potential personalized therapy that is under development to be
specifically tailored to each patient's disease profile. Tcelna is
manufactured using ImmPath™, Opexa's proprietary method for the production of
a patient-specific T-cell immunotherapy, which encompasses the collection of
blood from the MS patient, isolation of peripheral blood mononuclear cells,
generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised
against selected peptides from myelin basic protein (MBP), myelin
oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the
return of these expanded, irradiated T-cells back to the patient. These
attenuated T-cells are reintroduced into the patient via subcutaneous
injection to trigger a therapeutic immune system response.
Opexa is currently conducting a Phase IIb study of Tcelna. Named “Abili-T,”
the trial is a randomized, double-blind, placebo-controlled clinical study in
patients who demonstrate evidence of disease progression with or without
associated relapses. The trial is expected to enroll 180 patients at
approximately 30 leading clinical sites in the U.S. and Canada with each
patient receiving two annual courses of Tcelna treatment consisting of five
subcutaneous injections per year. The trial’s primary efficacy outcome is the
percentage of brain volume change (atrophy) at 24 months. Study investigators
will also measure several important secondary outcomes commonly associated
with MS, including disease progression as measured by the Expanded Disability
Status Scale (EDSS), annualized relapse rate and changes in disability as
measured by EDSS and the MS Functional Composite.
For more information visit the Opexa Therapeutics website at
Opexa Therapeutics, Inc.
Press spacebar to pause and continue. Press esc to stop.